international experts will present the state of the art of psychedelic science and psychedelic psychotherapy studies, including:
- biological and neurological effects of psychedelic substances
- mdma-(ecstasy) assisted psychotherapy for the treatment of posttraumatic stress disorder (ptsd)
- psychedelic psychotherapy for treating anxiety and depression associated with life-threatening illnesses
- mystical-type experiences catalyzed by psychedelics and their therapeutic implications
- psychedelics’ role in the treatment of drug addiction
- psilocybin research with obsessive-compulsive disorder
- standards for conducting psychedelic psychotherapy research
the intended learning objectives for medical doctors and ancillary medical professionals are:
1) apply new techniques and strategies for enhancing communication, trust and therapeutic effectiveness with patients in their regular therapeutic practices, based on transferable lessons learned from presentations about recent psychedelic research and associated psychedelic psychotherapy techniques.
2) counsel patients and their families more effectively with drug-related issues and/or questions by implementing knowledge of recent scientific research about the mechanisms of action and potential risks and benefits of psychedelic drugs.
3) make informed decisions about initiating and/or improving their own clinical research with psychedelics, by having additional information on special regulatory issues, current research methodologies and therapeutic approaches.
4) evaluate methodological rigor of clinical trials of psychedelic-assisted psychotherapy, and research in general, in light of presentations about the design of state-of-the-art research in the field.
5) implement compassionate psychedelic psychotherapy intervention techniques in emergency room situations and in private practice when attending to patients undergoing acute psychedelic crises.
6) refer patients with relevant medical conditions to active clinical trials.
7) post conference, be able to share with colleagues knowledge from recent scientific studies pertaining to the medical and non-medical use of psychedelic drugs.
this activity has been planned and implemented in accordance with the institute for medical quality and the california medical association’s cme accreditation standards (imq/cma) through the joint-sponsorship of cme consultants and the multidisciplinary association for psychedelic studies (maps). Cme consultants is accredited by imq/cma to provide continuing medical education for physicians. Cme consultants takes responsibility for the content, quality and scientific integrity of this cme activity.
cme consultants designates this educational activity for a maximum of 15.0 ama pra category 1 credit™. physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the cma certification in continuing medical education.